Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.
Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.
The tragedy in Newtown should bring gun owners and opponents together.
Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.
Medical innovation is increasing but ever-escalating drug prices aren't sustainable.
TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.
Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.
A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.
The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.
An FDA decision expected this week could easily go against United Therapeutics.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.